HARBIN, China, June 2 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced that its wholly owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, Heilongjiang Tianlong Pharmaceutical, Inc. and Heilongjiang Haina Pharmaceutical, Inc. have been recognized as Heilongjiang's Model Companies by the Heilongjiang Provincial Government.
Each year, the Heilongjiang Provincial Government will select 200 to 300 Model Companies from over 20,000 companies in Heilongjiang Province. These Model Companies are viewed as leaders in their respective industries and have established a track record in demonstrating responsibility to their employees, customers and the overall public.
"We are honored that our operating subsidiaries have been designated as Model Companies and look forward to continue to provide leadership in the pharmaceutical industry throughout Heilongjiang Province," said Mr. Yanqing Liu, China Sky One Medical's Chief Executive Officer. "As recognized by these designations, China Sky One Medical has been and remains committed to serving our customers, providing good working environment for our employees and positively contributing to the society. We believe that building and maintaining a high quality brand and strong corporate image will support the Company's long term growth and development."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include the designation of Model Companies and its effect on the Company's operational results. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the ability to develop new technologies and products, market acceptance of new product launches, achievability of management's estimates of product sales, the effect of changing economic conditions in The People's Republic of China, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact: Company Contact: China Sky One Medical, Inc. Mr. Stanley Hao, CFO Tel: +86-451-8703-2617 Email: email@example.com Investor Relations Contact: CCG Investor Relations Ms. Lei Huang, Account Manager Tel: +1-646-833-3417 Email: firstname.lastname@example.org Web: http://www.ccgirasia.com Ms. Mabel Zhang, Vice President Tel: +1-310-954-1353 Email: email@example.com
SOURCE China Sky One Medical, Inc.